Cognitive and Memory Enhancer Drugs Market Size by Product, Application, Region – Revenue Pool Analysis, Margin Structure Assessment, Capital Flow Trends, Competitive Benchmarking & Forecast to 2030
Overview
The Cognitive and Memory Enhancer Drugs Market size was valued at USD 5.98 Billion in 2023 and the total Cognitive and Memory Enhancer Drugs revenue is expected to grow at a CAGR of 5.68% from 2024 to 2030, reaching nearly USD 8.81 Billion.
Cognitive and Memory Enhancer Drugs Market Overview:
Attempts to improve cognitive function in patients with brain disorders has become the focus of intensive research. Cognitive and Memory Enhancer Drugs are used to improve memory, increase mental alertness, enhance concentration, and boost the energy levels of an individual. Some cognitive enhancers are designed to treat conditions such as sleepiness or narcolepsy and to improve attention and focus in people with attention disorders.
To Know About The Research Methodology :- Request Free Sample Report
Cognitive and Memory Enhancer Drugs Market Dynamics:
Rising prevalence of neurological disorders is the key driving factor for the market growth.
Incidences of neurological disorders like dementia, Alzheimer and Parkinson’s increase demand a reliable treatment. Hence, the individuals affected with these disorders are the prominent receivers of cognitive and memory enhancer drugs. This factor propels the market growth. Worldwide, around 50 million people have dementia, and there are nearly 10 million new cases every year. Besides this, cognitive drugs are also used in the field of academics and athletics. Also, ongoing clinical trials for the development of potential drugs contribute to the market growth. The high cost involved in the R&D activities of the drugs and legal & ethical contradictions may affect the market negatively in the forecast period.
The report has profiled key players in the market from different regions. However, the report has considered all market leaders, followers, and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and the report has come up with recommendations for a future hot spot in the APAC region.
Cognitive and Memory Enhancer Drugs Market Segment Analysis:
Based on the product, the Namenda held the largest share of xx% in 2023 and is expected to dominate during forecast years. It is the first drug approved for Alzheimer's and dementia by the FDA and helps in slowing down the disease progression. Memantine (Namenda) and a combination of Memantine and donepezil (Namzaric) are approved by the FDA for the treatment of moderate to severe Alzheimer’s. Namenda regulates the activity of glutamate, a chemical involved in information processing, storage, and retrieval, and also improves mental function and ability to perform daily activities for some people. New psychostimulant modafinil (Provigil) has been approved by FDA for improving alertness, a key factor in cognitive performance.
Based on the application, the academic performance segment is expected to dominate the global market during the forecast period. The academic performance segment is projected to register the fastest growth at a CAGR of 10.2% during the forecast period, owing to the benefits provided by these drugs to students in terms of improvement of concentration, memory, and performance. Also, the disease treatment segment is expected to be the fastest-growing segment owing to the increase in the prevalence of Asthma, Parkinson's, and Alzheimer's disease.
Cognitive and Memory Enhancer Drugs Market Regional Insights
North America anticipated to dominate the global market, followed by Europe.
Increasing Alzheimer’s patient pool in the region and increased healthcare expenditure for the long-term care of these patients drives the market growth in this region. More than 6 million Americans of all ages have Alzheimer's. An estimated 6.2 million Americans age 65 and older are living with Alzheimer's dementia in 2021. Apart from this, rising awareness amongst the people due to government initiatives undertaken about cognitive diseases fuels the market growth.
Asia Pacific is expected to witness lucrative growth:
The region is expected to witness the fastest growth owing to the rising adoption of cognitive drugs as there is an increasing geriatric population, especially in affluent countries of the region like Japan and India. Improved medical infrastructure, increased healthcare expenditure, medical tourism presence of large target population suffering from dementia, improved standard of living, and rise in disposable income drives the market.
The report also helps in understanding Global Market dynamics, structure by analyzing the market segments and project the Global Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Market make the report investor’s guide.
Cognitive and Memory Enhancer Drugs Market Scope: Inquire before buying
| Cognitive and Memory Enhancer Drugs Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2023 | Forecast Period: | 2024-2030 |
| Historical Data: | 2018 to 2023 | Market Size in 2023: | USD 5.98 Bn. |
| Forecast Period 2024 to 2030 CAGR: | 5.68% | Market Size in 2030: | USD 8.81 Bn. |
| Segments Covered: | by Product | Namenda Provigil Aricept Razadyne Exelon Adderall Ritalin Others |
|
| by Application | Disease Treatment Athletic Performance Academic Performance |
||
Cognitive and Memory Enhancer Drugs Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Cognitive and Memory Enhancer Drugs Market Key Players:
1. Johnson & Johnson
2. Pfizer Inc.
3. Novartis AG
4. Eisai Co., Ltd.
5. Cephalon, Inc. (Teva Pharmaceutical Industries Ltd.)
6. AlternaScript LLC
7. Shire
8. Ceretropic
9. Allergan Plc.
10. Takeda Pharmaceutical Company
Frequently Asked Questions:
1. Which region has the largest share in Global Cognitive and Memory Enhancer Drugs Market?
Ans: North America region held the highest share in 2023.
2. What was the Global Cognitive and Memory Enhancer Drugs Market size in 2023?
Ans: The Global Cognitive and Memory Enhancer Drugs Market size was USD 5.98 Billion in 2023.
3. What is scope of the Global Cognitive and Memory Enhancer Drugs market report?
Ans: Global Cognitive and Memory Enhancer Drugs Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. Who are the key players in Global Cognitive and Memory Enhancer Drugs market?
Ans: The important key players in the Global Cognitive and Memory Enhancer Drugs Market are – Johnson & Johnson, Pfizer Inc., Novartis AG, Eisai Co., Ltd., Cephalon, Inc. (Teva Pharmaceutical Industries Ltd.), AlternaScript LLC, Shire, Ceretropic, Allergan Plc., and Takeda Pharmaceutical Company.
5. What is the study period of this market?
Ans: The Global Cognitive and Memory Enhancer Drugs Market is studied from 2023.